Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Phone app and coaching aim to boost heart recovery in seniors

NCT ID NCT07390006

Symptom relief Sponsor: Mahidol University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new care program for older adults in Thailand who have had a heart attack. The program combines in-person education, motivational counseling, and a mobile app to help them adopt healthy habits and track their recovery. Researchers will measure if this approach improves their health, satisfaction, and reduces unplanned hospital visits over 12 weeks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Jan 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Inclusion Criteria for the quantitative phase: 1. Aged ≥ 60 years old. 2. Diagnosed with ACS and received PCI within 3-12 months. 3. Being familiar with using a smartphone or tablet with the LINE application, either personally or through a caregiver or family member. 4. No cognitive impairment assessed by the 6-Item Cognitive Function Test-Thai Version (6CIT), score less than 8. 5. Able to communicate in the Thai language by speaking, listening, reading, and writing in Thai sufficiently. 6. Voluntarily agreed to participate and has signed the informed consent form. Inclusion Criteria for the qualitative phase: 1. Participate in the experimental group and complete the program. 2. Extreme case sampling involves selecting the top 6 highest and top 6 lowest scores for healthy behavior. 3. Willing to participate in a one-on-one in-depth interview. Exclusion Criteria: Exclusion Criteria for the quantitative phase: 1. Have clinical contraindications to physical exercise (i.e. unstable angina, uncontrolled arrhythmias, systolic \>180 mmHg or diastolic \>110 mmHg, an LVEF of less than 40%, recent major surgery within 12 weeks such as CABG, valve replacement, or orthopedic surgery), or any serious medical condition that the cardiologist considers unsafe to perform physical activity. 2. Visual or hearing impairments that cannot be adequately managed with medical devices (e.g., eyeglasses or hearing aids) and that interfere with the ability to participate in study activities or communicate effectively.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome/ myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndrome/ myocardial infarction Coronary artery disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Faculty of Medicine Ramathibodi Hospital, Mahidol University

    Bangkok, 10400, Thailand

More trials for these conditions

Other studies related to the condition(s) this trial covers.